• 1

    JemalASiegelRXuJWardE. Cancer statistics, 2010. CA Cancer J Clin2010;60:277300.

  • 2

    BrownLMDevesaSSChowWH. Incidence of adenocarcinoma of the esophagus among white americans by sex, stage, and age. J Natl Cancer Inst2008;100:11841187.

    • Search Google Scholar
    • Export Citation
  • 3

    TriversKFSabatinoSAStewartSL. Trends in esophageal cancer incidence by histology, United States, 1998–2003. Int J Cancer2008;123:14221428.

    • Search Google Scholar
    • Export Citation
  • 4

    BosettiCLeviFFerlayJ. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer2008;122:11181129.

  • 5

    KamangarFDoresGMAndersonWF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol2006;24:21372150.

    • Search Google Scholar
    • Export Citation
  • 6

    CorleyDABufflerPA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol2001;30:14151425.

    • Search Google Scholar
    • Export Citation
  • 7

    PickensAOrringerMB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg2003;76:S13671369.

  • 8

    SiewertJRKatjaO. Are squamous and adenocarcinomas of the esophagus the same disease?Semin Radiat Oncol2007;17:3844.

  • 9

    SiewertJRSteinHJFeithM. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg2001;234:360367.

    • Search Google Scholar
    • Export Citation
  • 10

    FreedmanNDAbnetCCLeitzmannMF. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol2007;165:14241433.

    • Search Google Scholar
    • Export Citation
  • 11

    EngelLSChowWHVaughanTL. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst2003;95:14041413.

  • 12

    LagergrenJBergstromRLindgrenANyrenO. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer2000;85:340346.

    • Search Google Scholar
    • Export Citation
  • 13

    GammonMSchoenbergJAhsanH. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst1997;89:12771284.

    • Search Google Scholar
    • Export Citation
  • 14

    CookMBKamangarFWhitemanDC. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international beacon consortium. J Natl Cancer Inst2010;102:13441353.

    • Search Google Scholar
    • Export Citation
  • 15

    ChowWHBlotWJVaughanTL. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst1998;90:150155.

    • Search Google Scholar
    • Export Citation
  • 16

    VaughanTLDavisSKristalAThomasDB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev1995;4:8592.

    • Search Google Scholar
    • Export Citation
  • 17

    LagergrenJBergstromRNyrenO. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med1999;130:883890.

    • Search Google Scholar
    • Export Citation
  • 18

    Morris BrownLSwansonCAGridleyG. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst1995;87:104109.

  • 19

    ChowWHFinkleWDMcLaughlinJK. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA1995;274:474477.

    • Search Google Scholar
    • Export Citation
  • 20

    LagergrenJBergstromRLindgrenANyrenO. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med1999;340:825831.

    • Search Google Scholar
    • Export Citation
  • 21

    CossentinoMJWongRK. Barrett's esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis2003;14:128135.

  • 22

    CameronAJRomeroY. Symptomatic gastro-oesophageal reflux as a risk factor for oesophageal adenocarcinoma. Gut2000;46:754755.

  • 23

    SharmaP. Clinical practice. Barrett's esophagus. N Engl J Med2009;361:25482556.

  • 24

    AnandasabapathySJhambJDavilaM. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Cancer2007;109:668674.

    • Search Google Scholar
    • Export Citation
  • 25

    GopalDVLiebermanDAMagaretN. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. Dig Dis Sci2003;48:15371541.

    • Search Google Scholar
    • Export Citation
  • 26

    DasAThomasSZablotskaLB. Association of esophageal adenocarcinoma with other subsequent primary cancers. J Clin Gastroenterol2006;40:405411.

    • Search Google Scholar
    • Export Citation
  • 27

    EdgeSBByrdDRComptonCC. AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer; 2010.

  • 28

    RiceTWRuschVWApperson-HansenC. Worldwide esophageal cancer collaboration. Dis Esophagus2009;22:18.

  • 29

    KimTJKimHYLeeKWKimMS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics2009;29:403421.

    • Search Google Scholar
    • Export Citation
  • 30

    SiewertJR. Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology, and extent of resection. Dis Esophagus1996;9:173182.

    • Search Google Scholar
    • Export Citation
  • 31

    SiewertJRFeithMWernerMSteinHJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg2000;232:353361.

    • Search Google Scholar
    • Export Citation
  • 32

    WangKKSamplinerRE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol2008;103:788797.

    • Search Google Scholar
    • Export Citation
  • 33

    AnconaERuolASantiS. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer2001;91:21652174.

    • Search Google Scholar
    • Export Citation
  • 34

    RohatgiPRSwisherSGCorreaAM. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer2005;104:13491355.

    • Search Google Scholar
    • Export Citation
  • 35

    SchneiderPMBaldusSEMetzgerR. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg2005;242:684692.

    • Search Google Scholar
    • Export Citation
  • 36

    BrucherBLBeckerKLordickF. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer2006;106:21192127.

    • Search Google Scholar
    • Export Citation
  • 37

    LangerROttKFeithM. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol2009;22:15551563.

    • Search Google Scholar
    • Export Citation
  • 38

    MeredithKLWeberJMTuragaKK. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol2010;17:11591167.

    • Search Google Scholar
    • Export Citation
  • 39

    ChirieacLRSwisherSGAjaniJA. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer2005;103:13471355.

    • Search Google Scholar
    • Export Citation
  • 40

    MandardAMDalibardFMandardJC. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer1994;73:26802686.

    • Search Google Scholar
    • Export Citation
  • 41

    WuTTChirieacLRAbrahamSC. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol2007;31:5864.

    • Search Google Scholar
    • Export Citation
  • 42

    DreilichMWandersABrattstromD. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus2006;19:224231.

    • Search Google Scholar
    • Export Citation
  • 43

    ReicheltUDuesedauPTsourlakisMC. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol2007;20:120129.

    • Search Google Scholar
    • Export Citation
  • 44

    SchoppmannSFJeschBFriedrichJ. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol2010;34:18681873.

  • 45

    MoelansCBvan DiestPJMilneANOfferhausGJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int2011;2010:674182.

    • Search Google Scholar
    • Export Citation
  • 46

    GravalosCJimenoA. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol2008;19:15231529.

  • 47

    TannerMHollmenMJunttilaTT. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol2005;16:273278.

    • Search Google Scholar
    • Export Citation
  • 48

    BangYChungHXuJ. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4556.

    • Search Google Scholar
    • Export Citation
  • 49

    BangYJVan CutsemEFeyereislovaA. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet2010;376:687697.

    • Search Google Scholar
    • Export Citation
  • 50

    HofmannMStossOShiD. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology2008;52:797805.

    • Search Google Scholar
    • Export Citation
  • 51

    CunninghamDAllumWHStenningSP. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med2006;355:1120.

    • Search Google Scholar
    • Export Citation
  • 52

    TepperJKrasnaMJNiedzwieckiD. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol2008;26:10861092.

    • Search Google Scholar
    • Export Citation
  • 53

    AloiaTAHarpoleDHReedCE. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg2001;72:859866.

    • Search Google Scholar
    • Export Citation
  • 54

    LuthraRWuTTLuthraMG. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol2006;24:259267.

    • Search Google Scholar
    • Export Citation
  • 55

    McManusDTOlaruAMeltzerSJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res2004;64:15611569.

  • 56

    NgTVezeridisMP. Advances in the surgical treatment of esophageal cancer. J Surg Oncol2010;101:725729.

  • 57

    WaltherBJohanssonJJohnssonF. Cervical or thoracic anastomosis after esophageal resection and gastric tube reconstruction: a prospective randomized trial comparing sutured neck anastomosis with stapled intrathoracic anastomosis. Ann Surg2003;238:803812.

    • Search Google Scholar
    • Export Citation
  • 58

    UrschelJDBlewettCJBennettWF. Handsewn or stapled esophagogastric anastomoses after esophagectomy for cancer: meta-analysis of randomized controlled trials. Dis Esophagus2001;14:212217.

    • Search Google Scholar
    • Export Citation
  • 59

    KlinkCDBinneboselMSchneiderM. Operative outcome of colon interposition in the treatment of esophageal cancer: a 20-year experience. Surgery2010;147:491496.

    • Search Google Scholar
    • Export Citation
  • 60

    VisbalALAllenMSMillerDL. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg2001;71:18031808.

  • 61

    OrringerMBMarshallBChangAC. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg2007;246:363372.

  • 62

    HulscherJBFvan SandickJWde BoerAG. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med2002;347:16621669.

    • Search Google Scholar
    • Export Citation
  • 63

    ChangACJiHBirkmeyerNJ. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg2008;85:424429.

  • 64

    ForshawMJGossageJAOckrimJ. Left thoracoabdominal esophagogastrectomy: still a valid operation for carcinoma of the distal esophagus and esophagogastric junction. Dis Esophagus2006;19:340345.

    • Search Google Scholar
    • Export Citation
  • 65

    LuketichJDAlvelo-RiveraMBuenaventuraPO. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg2003;238:486494.

  • 66

    ZinggUMcQuinnADiValentinoD. Minimally invasive versus open esophagectomy for patients with esophageal cancer. Ann Thorac Surg2009;87:911919.

    • Search Google Scholar
    • Export Citation
  • 67

    DeckerGCoosemansWDe LeynP. Minimally invasive esophagectomy for cancer. Eur J Cardiothorac Surg2009;35:1320.

  • 68

    LevyRMWizorekJShendeMLuketichJD. Laparoscopic and thoracoscopic esophagectomy. Adv Surg2010;44:101116.

  • 69

    PerryYFernandoHCBuenaventuraPO. Minimally invasive esophagectomy in the elderly. JSLS2002;6:299304.

  • 70

    BirkmeyerJDSiewersAEFinlaysonEV. Hospital volume and surgical mortality in the United States. N Engl J Med2002;346:11281137.

  • 71

    SteyerbergEWNevilleBAKoppertLB. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol2006;24:42774284.

    • Search Google Scholar
    • Export Citation
  • 72

    SwisherSGWynnPPutnamJB. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg2002;123:175183.

    • Search Google Scholar
    • Export Citation
  • 73

    KrasnaMJReedCEJaklitschMT. Thoracoscopic staging of esophageal cancer: a prospective, multiinstitutional trial. Cancer and Leukemia Group B Thoracic Surgeons. Ann Thorac Surg1995;60:13371340.

    • Search Google Scholar
    • Export Citation
  • 74

    HofstetterWL. Lymph node dissection in esophageal cancer. In: YangSCCameronDE eds. Current Therapy in Thoracic and Cardiovascular Surgery. Philadelphia, PA: Mosby, Inc; 2004:360363.

    • Search Google Scholar
    • Export Citation
  • 75

    GrothSSWhitsonBALiZ. Determination of the ideal number of lymph nodes to examine to optimize survival in patients with esophageal carcinoma: data from the surveillance epidemiology and end results database [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4528.

    • Search Google Scholar
    • Export Citation
  • 76

    PeyreCGHagenJADeMeesterSR. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg2008;248:979985.

    • Search Google Scholar
    • Export Citation
  • 77

    RizkNPIshwaranHRiceTW. Optimum lymphadenectomy for esophageal cancer. Ann Surg2010;251:4650.

  • 78

    FujitaHSueyoshiSYamanaH. Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy. World J Surg2001;25:424431.

    • Search Google Scholar
    • Export Citation
  • 79

    SoetiknoRKaltenbachTYehRGotodaT. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol2005;23:44904498.

    • Search Google Scholar
    • Export Citation
  • 80

    ConioMRepiciACestariR. Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. World J Gastroenterol2005;11:66506655.

    • Search Google Scholar
    • Export Citation
  • 81

    EllCMayAGossnerL. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology2000;118:670677.

    • Search Google Scholar
    • Export Citation
  • 82

    SeewaldSAkaraviputhTSeitzU. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc2003;57:854859.

    • Search Google Scholar
    • Export Citation
  • 83

    LarghiALightdaleCJRossAS. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy2007;39:10861091.

    • Search Google Scholar
    • Export Citation
  • 84

    LopesCVHelaMPesentiC. Circumferential endoscopic resection of Barrett's esophagus with high-grade dysplasia or early adenocarcinoma. Surg Endosc2007;21:820824.

    • Search Google Scholar
    • Export Citation
  • 85

    ChennatJKondaVJRossAS. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma—an American single-center experience. Am J Gastroenterol2009;104:26842692.

    • Search Google Scholar
    • Export Citation
  • 86

    GanzRAOverholtBFSharmaVK. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. multicenter registry. Gastrointest Endosc2008;68:3540.

    • Search Google Scholar
    • Export Citation
  • 87

    MaishMSDeMeesterSR. Endoscopic mucosal resection as a staging technique to determine the depth of invasion of esophageal adenocarcinoma. Ann Thorac Surg2004;78:17771782.

    • Search Google Scholar
    • Export Citation
  • 88

    OverholtBFLightdaleCJWangKK. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc2005;62:488498.

    • Search Google Scholar
    • Export Citation
  • 89

    PechOGossnerLMayA. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc2005;62:2430.

    • Search Google Scholar
    • Export Citation
  • 90

    ShaheenNJSharmaPOverholtBF. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med2009;360:22772288.

  • 91

    DumotJAVargoJJIIFalkGW. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc2009;70:635644.

    • Search Google Scholar
    • Export Citation
  • 92

    ShaheenNJGreenwaldBDPeeryAF. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc2010;71:680685.

    • Search Google Scholar
    • Export Citation
  • 93

    PechOBehrensAMayA. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut2008;57:12001206.

    • Search Google Scholar
    • Export Citation
  • 94

    KomanduriSSwansonGKeeferLJakateS. Use of a new jumbo forceps improves tissue acquisition of Barrett's esophagus surveillance biopsies. Gastrointest Endosc2009;70:10721078.

    • Search Google Scholar
    • Export Citation
  • 95

    GaurPSepesiBHofstetterWL. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer2011;117:6369.

    • Search Google Scholar
    • Export Citation
  • 96

    LarghiALightdaleCJMemeoL. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc2005;62:1623.

    • Search Google Scholar
    • Export Citation
  • 97

    ThomasTSinghRRagunathK. Trimodal imaging-assisted endoscopic mucosal resection of early Barrett's neoplasia. Surg Endosc2009;23:16091613.

    • Search Google Scholar
    • Export Citation
  • 98

    MannathJSubramanianVHawkeyCJRagunathK. Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett's esophagus: a meta-analysis. Endoscopy2010;42:351359.

    • Search Google Scholar
    • Export Citation
  • 99

    AnagnostopoulosGKYaoKKayeP. Novel endoscopic observation in Barrett's oesophagus using high resolution magnification endoscopy and narrow band imaging. Aliment Pharmacol Ther2007;26:501507.

    • Search Google Scholar
    • Export Citation
  • 100

    BarbourAPRizkNPGerdesH. Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction. J Am Coll Surg2007;205:593601.

    • Search Google Scholar
    • Export Citation
  • 101

    ChoiJKimSGKimJS. Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc2010;24:13801386.

    • Search Google Scholar
    • Export Citation
  • 102

    KeswaniRNEarlyDSEdmundowiczSA. Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. Gastrointest Endosc2009;69:12101217.

    • Search Google Scholar
    • Export Citation
  • 103

    BergmanJJ. The endoscopic diagnosis and staging of oesophageal adenocarcinoma. Best Pract Res Clin Gastroenterol2006;20:843866.

  • 104

    Vazquez-SequeirosENortonIDClainJE. Impact of EUS-guided fine-needle aspiration on lymph node staging in patients with esophageal carcinoma. Gastrointest Endosc2001;53:751757.

    • Search Google Scholar
    • Export Citation
  • 105

    Vazquez-SequeirosEWiersemaMJClainJE. Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology2003;125:16261635.

    • Search Google Scholar
    • Export Citation
  • 106

    LightdaleCJHeierSKMarconNE. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc1995;42:507512.

    • Search Google Scholar
    • Export Citation
  • 107

    VakilNMorrisAIMarconN. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol2001;96:17911796.

    • Search Google Scholar
    • Export Citation
  • 108

    RibeiroAFranceschiDParraJ. Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal cancer. Am J Gastroenterol2006;101:12161221.

    • Search Google Scholar
    • Export Citation
  • 109

    SarkariaISRizkNPBainsMS. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg2009;249:764767.

    • Search Google Scholar
    • Export Citation
  • 110

    LightdaleCJBotetJFKelsenDP. Diagnosis of recurrent upper gastrointestinal cancer at the surgical anastomosis by endoscopic ultrasound. Gastrointest Endosc1989;35:407412.

    • Search Google Scholar
    • Export Citation
  • 111

    ReidBJLevineDSLongtonG. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol2000;95:16691676.

    • Search Google Scholar
    • Export Citation
  • 112

    PrasadGABansalASharmaPWangKK. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol2010;105:14901502.

    • Search Google Scholar
    • Export Citation
  • 113

    SharmaPDentJArmstrongD. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology2006;131:13921399.

    • Search Google Scholar
    • Export Citation
  • 114

    ChennatJWaxmanI. Endoscopic treatment of Barrett's esophagus: from metaplasia to intramucosal carcinoma. World J Gastroenterol2010;16:37803785.

    • Search Google Scholar
    • Export Citation
  • 115

    NewaishyGAReadGADuncanWKerrGR. Results of radical radiotherapy of squamous cell carcinoma of the oesophagus. Clin Radiol1982;33:347352.

    • Search Google Scholar
    • Export Citation
  • 116

    OkawaTKitaMTanakaMIkedaM. Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys1989;17:4954.

    • Search Google Scholar
    • Export Citation
  • 117

    SunDR. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys1989;16:329334.

    • Search Google Scholar
    • Export Citation
  • 118

    ShiXHYaoWLiuT. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol1999;51:2126.

  • 119

    al-SarrafMMartzKHerskovicA. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol1997;15:277284. [Erratum in J Clin Oncol 1997;15:866.]

    • Search Google Scholar
    • Export Citation
  • 120

    HerskovicAMartzKal-SarrafM. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med1992;326:15931598.

    • Search Google Scholar
    • Export Citation
  • 121

    HosokawaMShiratoHOharaM. Intraoperative radiation therapy to the upper mediastinum and nerve-sparing three-field lymphadenectomy followed by external beam radiotherapy for patients with thoracic esophageal carcinoma. Cancer1999;86:613.

    • Search Google Scholar
    • Export Citation
  • 122

    ChandraAGuerreroTMLiuHH. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol2005;77:247253.

    • Search Google Scholar
    • Export Citation
  • 123

    FuWHWangLHZhouZM. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma. World J Gastroenterol2004;10:10981102.

    • Search Google Scholar
    • Export Citation
  • 124

    MayoCSUrieMMFitzgeraldTJ. Hybrid IMRT for treatment of cancers of the lung and esophagus. Int J Radiat Oncol Biol Phys2008;71:14081418.

    • Search Google Scholar
    • Export Citation
  • 125

    NuttingCMBedfordJLCosgroveVP. Intensity-modulated radiotherapy reduces lung irradiation in patients with carcinoma of the oesophagus. Front Radiat Ther Oncol2002;37:128131.

    • Search Google Scholar
    • Export Citation
  • 126

    ArnottSJDuncanWKerrGR. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother Oncol1992;24:108113.

    • Search Google Scholar
    • Export Citation
  • 127

    TenierePHayJMFingerhutAFagniezPL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet1991;173:123130.

    • Search Google Scholar
    • Export Citation
  • 128

    WangMGuXZYinWB. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. Int J Radiat Oncol Biol Phys1989;16:325327.

    • Search Google Scholar
    • Export Citation
  • 129

    ArnottSJDuncanWGignouxM. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys1998;41:579583.

    • Search Google Scholar
    • Export Citation
  • 130

    SurRKDondeBLevinVCMannellA. Fractionated high dose rate intraluminal brachytherapy in palliation of advanced esophageal cancer. Int J Radiat Oncol Biol Phys1998;40:447453.

    • Search Google Scholar
    • Export Citation
  • 131

    GasparLEQianCKochaWI. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report. Int J Radiat Oncol Biol Phys1997;37:593599.

    • Search Google Scholar
    • Export Citation
  • 132

    KleinbergLForastiereAA. Chemoradiation in the management of esophageal cancer. J Clin Oncol2007;25:41104117.

  • 133

    CooperJSGuoMDHerskovicA. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA1999;281:16231627.

    • Search Google Scholar
    • Export Citation
  • 134

    MinskyBDPajakTFGinsbergRJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol2002;20:11671174.

    • Search Google Scholar
    • Export Citation
  • 135

    LiQQLiuMZHuYH. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus2010;23:253259.

    • Search Google Scholar
    • Export Citation
  • 136

    RuppertBNWatkinsJMShiraiK. Cisplatin/irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol2010;33:346352.

    • Search Google Scholar
    • Export Citation
  • 137

    GwynneSHurtCEvansM. Definitive chemoradiation for oesophageal cancer - a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol (R Coll Radiol)2011;23:182188.

    • Search Google Scholar
    • Export Citation
  • 138

    ConroyTYatagheneYEtiennePL. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer2010;103:13491355.

    • Search Google Scholar
    • Export Citation
  • 139

    MeertenEVvan RijCTesselaarME. Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: a phase II study [abstract]. J Clin Oncol2010;28(Suppl 1):Abstract e14508.

    • Search Google Scholar
    • Export Citation
  • 140

    IyerRWilkinsonNDemmyTJavleM. Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol2004;11:665673.

    • Search Google Scholar
    • Export Citation
  • 141

    UrschelJDVasanH. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg2003;185:538543.

    • Search Google Scholar
    • Export Citation
  • 142

    FioricaFDi BonaDSchepisF. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut2004;53:925930.

    • Search Google Scholar
    • Export Citation
  • 143

    CenPCorreaAMLeJH. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus2009;22:3241. [Erratum in Dis Esophagus 2009;22:289.]

    • Search Google Scholar
    • Export Citation
  • 144

    GebskiVBurmeisterBSmithersBM. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol2007;8:226234.

    • Search Google Scholar
    • Export Citation
  • 145

    SwisherSGHofstetterWKomakiR. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg2010;90:892898; discussion 898–899.

    • Search Google Scholar
    • Export Citation
  • 146

    StahlMWalzMKStuschkeM. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol2009;27:851856.

    • Search Google Scholar
    • Export Citation
  • 147

    SchnirerIIKomakiRYaoJC. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol2001;24:9195.

    • Search Google Scholar
    • Export Citation
  • 148

    KleinbergLKniselyJPHeitmillerR. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys2003;56:328334.

    • Search Google Scholar
    • Export Citation
  • 149

    KhushalaniNILeichmanCGProulxG. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol2002;20:28442850.

    • Search Google Scholar
    • Export Citation
  • 150

    MeluchAAGrecoFAGrayJR. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J2003;9:251260.

    • Search Google Scholar
    • Export Citation
  • 151

    UrbaSGOrringerMBIanettonniM. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer2003;98:21772183.

    • Search Google Scholar
    • Export Citation
  • 152

    AjaniJAWalshGKomakiR. Preoperative induction of CPT- and11 cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer2004;100:23472354.

    • Search Google Scholar
    • Export Citation
  • 153

    LiaoZZhangZJinJ. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys2004;60:14841493.

    • Search Google Scholar
    • Export Citation
  • 154

    PasiniFde ManzoniGPedrazzaniC. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol2005;16:11331139.

    • Search Google Scholar
    • Export Citation
  • 155

    TewWPMinskyBBainsM. Phase II trial of preoperative combined modality therapy for esophageal carcinoma: induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy [abstract]. J Clin Oncol2005(Suppl 1);23:Abstract 4017.

    • Search Google Scholar
    • Export Citation
  • 156

    van MeertenEMullerKTilanusHW. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer2006;94:13891394.

    • Search Google Scholar
    • Export Citation
  • 157

    HiharaJYoshidaKHamaiY. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. Anticancer Res2007;27:25972603.

    • Search Google Scholar
    • Export Citation
  • 158

    LorenzenSBrucherBZimmermannF. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer2008;99:10201026.

    • Search Google Scholar
    • Export Citation
  • 159

    RiveraFGalanMTaberneroJ. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys2009;75:14301436.

    • Search Google Scholar
    • Export Citation
  • 160

    RuhstallerTWidmerLSchullerJC. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol2009;20:15221528.

    • Search Google Scholar
    • Export Citation
  • 161

    SharmaRYangGYNavaHR. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC) [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract e15619.

    • Search Google Scholar
    • Export Citation
  • 162

    ZemanovaMPetruzelkaLPazdroA. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. Dis Esophagus2010;23:160167.

    • Search Google Scholar
    • Export Citation
  • 163

    CzitoBGKelseyCRHurwitzHI. A phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys2007;67:10021007.

    • Search Google Scholar
    • Export Citation
  • 164

    SpigelDRGrecoFAMeluchAA. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. J Clin Oncol2010;28:22132219.

    • Search Google Scholar
    • Export Citation
  • 165

    NygaardKHagenSHansenHS. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg1992;16:11041109.

    • Search Google Scholar
    • Export Citation
  • 166

    WalshTNNoonanNHollywoodD. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med1996;335:462467.

    • Search Google Scholar
    • Export Citation
  • 167

    BossetJFGignouxMTribouletJP. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med1997;337:161167.

    • Search Google Scholar
    • Export Citation
  • 168

    AjaniJAKomakiRPutnamJB. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer2001;92:279286.

    • Search Google Scholar
    • Export Citation
  • 169

    UrbaSGOrringerMBTurrisiA. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol2001;19:305313.

    • Search Google Scholar
    • Export Citation
  • 170

    BainsMSStojadinovicAMinskyB. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg2002;124:270277.

    • Search Google Scholar
    • Export Citation
  • 171

    KaklamanosIGWalkerGRFerryK. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol2003;10:754761.

    • Search Google Scholar
    • Export Citation
  • 172

    BurmeisterBHSmithersBMGebskiV. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol2005;6:659668.

    • Search Google Scholar
    • Export Citation
  • 173

    KleinbergLPowellMEForastiereAA. Survival outcome of E1201: an Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4532.

    • Search Google Scholar
    • Export Citation
  • 174

    GaastAVvan HagenPHulshofM. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study [abstract]. J Clin Oncol2010;28(Suppl 1):Abstract 4004.

    • Search Google Scholar
    • Export Citation
  • 175

    MarietteCSeitzJFMaillardE. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCD 9901 [abstract]. J Clin Oncol2010;28(Suppl 1):Abstract 4005.

    • Search Google Scholar
    • Export Citation
  • 176

    StahlMStuschkeMLehmannN. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol2005;23:23102317.

    • Search Google Scholar
    • Export Citation
  • 177

    BedenneLMichelPBoucheO. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol2007;25:11601168.

    • Search Google Scholar
    • Export Citation
  • 178

    StahlMWilkeHLehmannN. Long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4530.

    • Search Google Scholar
    • Export Citation
  • 179

    BedardELInculetRIMalthanerRA. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer2001;91:24232430.

    • Search Google Scholar
    • Export Citation
  • 180

    RiceTWAdelsteinDJChidelMA. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg2003;126:15901596.

    • Search Google Scholar
    • Export Citation
  • 181

    AdelsteinDJRiceTWRybickiLA. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol2009;4:12641269.

    • Search Google Scholar
    • Export Citation
  • 182

    MacdonaldJSSmalleySRBenedettiJ. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med2001;345:725730.

    • Search Google Scholar
    • Export Citation
  • 183

    MacdonaldJSBenedettiJSmalleyS. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008) [abstract]. J Clin Oncol2009(Suppl 1);27:Abstract 4515.

    • Search Google Scholar
    • Export Citation
  • 184

    KelsenDPGinsbergRPajakTF. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med1998;339:19791984.

    • Search Google Scholar
    • Export Citation
  • 185

    KelsenDPWinterKAGundersonLL. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol2007;25:37193725.

    • Search Google Scholar
    • Export Citation
  • 186

    Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet2002;359:17271733.

    • Search Google Scholar
    • Export Citation
  • 187

    AllumWHStenningSPBancewiczJ. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol2009;27:50625067.

    • Search Google Scholar
    • Export Citation
  • 188

    BoigeVPignonJSaint-AubertB. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4510.

    • Search Google Scholar
    • Export Citation
  • 189

    ThirionPGMichielsSLe MaitreA. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4512.

    • Search Google Scholar
    • Export Citation
  • 190

    HomsMYv d GaastASiersemaPD. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev2006:CD004063.

    • Search Google Scholar
    • Export Citation
  • 191

    ShahMASchwartzGK. Treatment of metastatic esophagus and gastric cancer. Semin Oncol2004;31:574587.

  • 192

    LeichmanLBerryBT. Experience with cisplatin in treatment regimens for esophageal cancer. Semin Oncol1991;18:6472.

  • 193

    Muhr-WilkenshoffFHinkelbeinWOhnesorgeI. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis2003;18:330334.

    • Search Google Scholar
    • Export Citation
  • 194

    EnzingerPCKulkeMHClarkJW. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci2005;50:22182223.

    • Search Google Scholar
    • Export Citation
  • 195

    BurkartCBokemeyerCKlumpB. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res2007;27:28452848.

    • Search Google Scholar
    • Export Citation
  • 196

    MuroKHamaguchiTOhtsuA. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol2004;15:955959.

    • Search Google Scholar
    • Export Citation
  • 197

    AlbertssonMJohanssonBFrieslandS. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol2007;24:407412.

    • Search Google Scholar
    • Export Citation
  • 198

    AjaniJAIlsonDHDaughertyK. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst1994;86:10861091.

    • Search Google Scholar
    • Export Citation
  • 199

    MauerAMKrautEHKraussSA. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol2005;16:13201325.

    • Search Google Scholar
    • Export Citation
  • 200

    IlsonDHWadleighRGLeichmanLPKelsenDP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol2007;18:898902.

    • Search Google Scholar
    • Export Citation
  • 201

    HarstrickABokemeyerCPreusserP. Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother Pharmacol1992;29:321322.

    • Search Google Scholar
    • Export Citation
  • 202

    IlsonDHAjaniJBhallaK. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol1998;16:18261834.

    • Search Google Scholar
    • Export Citation
  • 203

    IlsonDHForastiereAArquetteM. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J2000;6:316323.

    • Search Google Scholar
    • Export Citation
  • 204

    PetraschSWeltAReinacherA. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer1998;78:511514.

    • Search Google Scholar
    • Export Citation
  • 205

    AjaniJAFodorMBTjulandinSA. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol2005;23:56605667.

    • Search Google Scholar
    • Export Citation
  • 206

    Van CutsemEMoiseyenkoVMTjulandinS. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol2006;24:49914997.

    • Search Google Scholar
    • Export Citation
  • 207

    KimJYDoYRParkKU. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol2010;66:3136.

    • Search Google Scholar
    • Export Citation
  • 208

    Al-BatranSEHartmannJTHofheinzR. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol2008;19:18821887.

    • Search Google Scholar
    • Export Citation
  • 209

    ShankaranVMulcahyMFHochsterHS. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: preliminary results of a phase II study [abstract]. Presented at: 2009 Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 47.

    • Search Google Scholar
    • Export Citation
  • 210

    OvermanMJKazmiSMJhambJ. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer2010;116:14461453.

    • Search Google Scholar
    • Export Citation
  • 211

    TebbuttNCCumminsMMSourjinaT. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer2010;102:475481.

    • Search Google Scholar
    • Export Citation
  • 212

    ArnoldDThuss-PatiencePCSteinA. Docetaxel, oxaliplatin, and capecitabine (TEX regimen) in patients with advanced or metastatic gastric or gastroesophageal cancer (GC): results from a phase II trial of the German AIO group [abstract]. J Clin Oncol2010;28:Abstract 4099.

    • Search Google Scholar
    • Export Citation
  • 213

    ShahMAShibataSStollerRG. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE) [abstract]. J Clin Oncol2010;28:Abstract 4014.

    • Search Google Scholar
    • Export Citation
  • 214

    IlsonDH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park)2004;18:2225.

  • 215

    RossPNicolsonMCunninghamD. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol2002;20:19962004.

    • Search Google Scholar
    • Export Citation
  • 216

    MillarJScullinPMorrisonA. Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer2005;93:11121116.

    • Search Google Scholar
    • Export Citation
  • 217

    UrbaSGChanskyKVanVeldhuizenPJ. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group study. Invest New Drugs2004;22:9197.

    • Search Google Scholar
    • Export Citation
  • 218

    AjaniJ. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer2006;107:221231.

  • 219

    CunninghamDStarlingNRaoS. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med2008;358:3646.

  • 220

    AssersohnLBrownGCunninghamD. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol2004;15:6469.

    • Search Google Scholar
    • Export Citation
  • 221

    WolffKWeinAReulbachU. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs2009;20:165173.

    • Search Google Scholar
    • Export Citation
  • 222

    DankMZaluskiJBaroneC. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol2008;19:14501457.

    • Search Google Scholar
    • Export Citation
  • 223

    SamalinEAfchainPThezenasS. Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. Gastroenterol Clin Biolin press.

    • Search Google Scholar
    • Export Citation
  • 224

    LearyAAssersohnLCunninghamD. A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol2009;64:455462.

    • Search Google Scholar
    • Export Citation
  • 225

    MoehlerMKanzlerSGeisslerM. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol2010;21:7177.

    • Search Google Scholar
    • Export Citation
  • 226

    BurtnessBGibsonMEglestonB. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol2009;20:12421248.

    • Search Google Scholar
    • Export Citation
  • 227

    LustbergMBBekaii-SaabTYoungD. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol2010;5:713718.

    • Search Google Scholar
    • Export Citation
  • 228

    El-RayesBFShieldsAZalupskiM. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol2004;15:960965.

  • 229

    Al-BatranSEHartmannJTProbstS. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol2008;26:14351442.

    • Search Google Scholar
    • Export Citation
  • 230

    PippMMulkerinDWarrenD. A phase II trial of gemcitabine and 5-fluoruracil in advanced esophageal cancer [abstract]. Proc Am Soc Clin Oncol2001;20:Abstract 630.

    • Search Google Scholar
    • Export Citation
  • 231

    Morgan-MeadowsSMulkerinDBerlinJD. A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Oncology2005;69:130134.

    • Search Google Scholar
    • Export Citation
  • 232

    HomsMYVoestEESiersemaPD. Emerging drugs for esophageal cancer. Expert Opin Emerg Drugs2009;14:329339.

  • 233

    De VitaFOrdituraMInnocenteR. A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC) [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4546.

    • Search Google Scholar
    • Export Citation
  • 234

    GoldPJGoldmanBIqbalS. Cetuximab as second-line therapy in patients with metastatic esophageal cancer: a phase II Southwest Oncology Group Study [abstract]. J Clin Oncol2008;26(Suppl 1):Abtract 4536.

    • Search Google Scholar
    • Export Citation
  • 235

    KuGYShahMATangLH. Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 15580.

    • Search Google Scholar
    • Export Citation
  • 236

    LorenzenSSchusterTPorschenR. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol2009;20:16671673.

    • Search Google Scholar
    • Export Citation
  • 237

    PintoCDi FabioFSienaS. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol2007;18:510517.

    • Search Google Scholar
    • Export Citation
  • 238

    EnzingerPCBurtnessBHollisD. CALGB 80403/ECOG 1206: a randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer [abstract]. J Clin Oncol2010;28(Suppl 1):Abstract 4006.

    • Search Google Scholar
    • Export Citation
  • 239

    DragovichTMcCoySFenoglio-PreiserCM. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol2006;24:49224927.

    • Search Google Scholar
    • Export Citation
  • 240

    WainbergZALinLDiCarloB. Final results of a phase II study of modified FOLFOX6 (mFOLFOX6) and erlotinib (E) in patients with metastatic adenocarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ) [abstract]. J Clin Oncol2010;28(Suppl 1):Abstract 4050.

    • Search Google Scholar
    • Export Citation
  • 241

    IlsonDHKelsenDShahM. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer2011;117:14091414.

    • Search Google Scholar
    • Export Citation
  • 242

    EnzingerPCRyanDPReganEM. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4552.

    • Search Google Scholar
    • Export Citation
  • 243

    KelsenDJhawerMIlsonD. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase II clinical trial [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 4512.

    • Search Google Scholar
    • Export Citation
  • 244

    de GraafGWAyantundeAAParsonsSL. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol2007;33:988992.

  • 245

    RosenbaumSStergarHAntochG. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdominal Imaging2006;31:2535.

  • 246

    MundenRFMacapinlacHAErasmusJJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging2006;21:137145.

    • Search Google Scholar
    • Export Citation
  • 247

    van WestreenenHLWesterterpMBossuytPM. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol2004;22:38053812.

    • Search Google Scholar
    • Export Citation
  • 248

    FlamenPLerutAVan CutsemE. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol2000;18:32023210.

    • Search Google Scholar
    • Export Citation
  • 249

    FlamenPLerutTHaustermansK. Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. Q J Nucl Med Mol Imaging2004;48:96108.

    • Search Google Scholar
    • Export Citation
  • 250

    CerfolioRJBryantASOhjaB. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg2005;129:12321241.

    • Search Google Scholar
    • Export Citation
  • 251

    LordickFOttKKrauseBJ. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol2007;8:797805.

    • Search Google Scholar
    • Export Citation
  • 252

    LordickFMeyer Zum BueschenfeldeCHerrmannK. PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): the MUNICON-II study [abstract]. J Clin Oncol2011;29(Suppl 4):Abstract 3.

    • Search Google Scholar
    • Export Citation
  • 253

    FlamenPVan CutsemELerutA. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol2002;13:361368.

    • Search Google Scholar
    • Export Citation
  • 254

    SwisherSGErasmusJMaishM. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer2004;101:17761785.

    • Search Google Scholar
    • Export Citation
  • 255

    SongSYKimJHRyuJS. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys2005;63:10531059.

    • Search Google Scholar
    • Export Citation
  • 256

    LevineEAFarmerMRClarkP. Predictive value of 18-fluorodeoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg2006;243:472478.

    • Search Google Scholar
    • Export Citation
  • 257

    KonskiAAChengJDGoldbergM. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys2007;69:358363.

    • Search Google Scholar
    • Export Citation
  • 258

    MonjazebAMRiedlingerGAkliluM. Outcomes of patients with esophageal cancer staged with [(1)F] fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?J Clin Oncol2010;28:47144721.

    • Search Google Scholar
    • Export Citation
  • 259

    GillhamCMLuceyJAKeoganM. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer2006;95:11741179.

    • Search Google Scholar
    • Export Citation
  • 260

    SmithersBMCouperGCThomasJM. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus2008;21:151158.

    • Search Google Scholar
    • Export Citation
  • 261

    KlaeserBNitzscheESchullerJC. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multicenter trial (SAKK 75/02). Onkologie2009;32:724730.

    • Search Google Scholar
    • Export Citation
  • 262

    VallbohmerDHolscherAHDietleinM. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg2009;250:888894.

    • Search Google Scholar
    • Export Citation
  • 263

    MalikVLuceyJADuffyGJ. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med2010;51:18631869.

    • Search Google Scholar
    • Export Citation
  • 264

    van HeijlMOmlooJMvan Berge HenegouwenMI. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg2011;253:5663.

    • Search Google Scholar
    • Export Citation
  • 265

    ColasantoJMPrasadPNashMA. Nutritional support of patients undergoing radiation therapy for head and neck cancer. Oncology (Williston Park)2005;19:371379.

    • Search Google Scholar
    • Export Citation
  • 266

    OkenMMCreechRHTormeyDC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol1982;5:649655.

  • 267

    SchagCCHeinrichRLGanzPA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol1984;2:187193.

  • 268

    Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet2000;355:15881596.

    • Search Google Scholar
    • Export Citation
  • 269

    JagerEHeikeMBernhardH. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol1996;14:22742279.

    • Search Google Scholar
    • Export Citation
  • 270

    O'ConnellMJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer1989;63:10261030.

    • Search Google Scholar
    • Export Citation
  • 271

    HomsMYSteyerbergEWEijkenboomWM. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet2004;364:14971504.

    • Search Google Scholar
    • Export Citation
  • 272

    ShinJHSongHYKimJH. Comparison of temporary and permanent stent placement with concurrent radiation therapy in patients with esophageal carcinoma. J Vasc Interv Radiol2005;16:6774.

    • Search Google Scholar
    • Export Citation
  • 273

    RossWAAlkassabFLynchPM. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointest Endosc2007;65:7076.

    • Search Google Scholar
    • Export Citation
  • 274

    VerschuurEMSteyerbergEWKuipersEJSiersemaPD. Effect of stent size on complications and recurrent dysphagia in patients with esophageal or gastric cardia cancer. Gastrointest Endosc2007;65:592601.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1767 1767 106
PDF Downloads 199 199 8
EPUB Downloads 0 0 0